Download PDF
Aktuelle Neurologie 2008; 35(4): 160-168
DOI: 10.1055/s-2007-986404
Übersicht

© Georg Thieme Verlag KG Stuttgart · New York

Moderne Immuntherapie der multiplen Sklerose

State of the Art Therapy for Multiple SclerosisT.  Ziemssen1 , A.  Chan2
  • 1Multiple Sklerose Zentrum, Neurologische Universitätsklinik Carl Gustav Carus, Technische Universität, Dresden
  • 2Neurologische Klinik, Ruhr-Universität Bochum, St. Josef-Hospital, Bochum
Further Information

Publication History

Publication Date:
18 March 2008 (online)

Also available at
   Permissions and Reprints

Corrected by:

Moderne Immuntherapie der multiplen SkleroseAktuelle Neurologie 2008; 35(04): e1-e1
DOI: 10.1055/s-2008-1067373

Zusammenfassung

Wesentliche Fortschritte auf verschiedenen Gebieten der neuroimmunologischen Forschung haben im letzten Jahrzehnt zu einer deutlichen Erweiterung der zur Verfügung stehenden therapeutischen Möglichkeiten in der Behandlung der multiplen Sklerose geführt. Diese Fortschritte beinhalten ein verbessertes Verständnis zugrunde liegender pathogenetischer Veränderungen, biotechnologische Weiterentwicklungen, aber auch Fortentwicklungen in der Gestaltung klinischer Studien. In dieser Übersicht werden pathophysiologische Aspekte, klinische Rationale sowie die praktische Anwendung etablierter MS-Therapeutika diskutiert.

Abstract

Considerable progress in different fields of neuroimmunological research has led to a major increase in the therapeutic options available for the treatment of multiple sclerosis over the last decade. This progress not only includes advances in our understanding of the pathophysiology of MS, and biotechnological developments but also improvements in clinical trial design. Here, we will review pathophysiological aspects, clinical rationale and practical issues of current MS therapy.

Schlüsselwörter

multiple Sklerose - immunmodulatorische Therapie - Schubtherapie - Eskalationstherapie

Key words

multiple sclerosis - immunomodulatory therapy - relapse therapy - escalation therapy

Literatur

  • 1 Multiple Sklerose-Therapie-Konsensus-Gruppe (MSTKG) . Immunmodulatorische Stufentherapie der Multiplen Sklerose, Aktuelle Therapieempfehlungen (September 2006).  Nervenarzt. 2006;  77 1506-1518
    CrossrefPubMedSearch in Google Scholar
  • 2 Grauer O, Offenhausser M, Schmidt J. et al . [Glucocorticosteroid therapy in optic neuritis and multiple sclerosis. Evidence from clinical studies and practical recommendations].  Nervenarzt. 2001;  72 577-589
    CrossrefPubMedSearch in Google Scholar
  • 3 Gold R, Buttgereit F, Toyka K V. Mechanism of action of glucocorticosteroid hormones: possible implications for therapy of neuroimmunological disorders.  J Neuroimmunol. 2001;  117 1-8
    CrossrefPubMedSearch in Google Scholar
  • 4 Multiple Sklerose-Therapie-Konsensus-Gruppe (MSTKG) . Immunmodulatorische Stufentherapie der Multiplen Sklerose.  Nervenarzt. 2002;  73 556-563
    CrossrefPubMedSearch in Google Scholar
  • 5 Song I H, Gold R, Straub R H. et al . New glucocorticoids on the horizon: repress, don't activate!.  J Rheumatol. 2005;  32 1199-1207
    PubMedSearch in Google Scholar
  • 6 Weinshenker B G, O'Brien P C, Petterson T M. et al . A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease.  Ann Neurol. 1999;  46 878-886
    CrossrefPubMedSearch in Google Scholar
  • 7 Ruprecht K, Klinker E, Dintelmann T. et al . Plasma exchange for severe optic neuritis: treatment of 10 patients.  Neurology. 2004;  63 1081-1083
    CrossrefPubMedSearch in Google Scholar
  • 8 Schilling S, Linker R A, König F B. et al . Plasma exchange therapy for steroid-unresponsive multiple sclerosis relapses: clinical experience with 16 patients.  Nervenarzt. 2006;  77 430-438
    CrossrefPubMedSearch in Google Scholar
  • 9 Chan A, Gold R. Can pathological patterns be used to guide individualized multiple sclerosis therapy?.  Nature Clin Practice Neurology. 2006;  2 72-73
    PubMedSearch in Google Scholar
  • 10 Keegan M, König F, McClelland R. et al . Multiple sclerosis pathological subtype predicts treatment response to therapeutic plasma exchange.  Lancet. 2005;  366 579-582
    CrossrefPubMedSearch in Google Scholar
  • 11 Linker R A, Chan A, Sommer M. et al . Plasma exchange therapy for steroid-refractory superimposed relapses in secondary progressive multiple sclerosis.  J Neurol. 2007;  254 1288-1289
    CrossrefPubMedSearch in Google Scholar
  • 12 Yong V W. Differential mechanisms of action of interferon-beta and glatiramer acetate in MS.  Neurology. 2002;  59 802-808
    CrossrefPubMedSearch in Google Scholar
  • 13 Kappos L, Freedman M S, Polman C H. et al . Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study.  Lancet. 2007;  370 389-397
    CrossrefPubMedSearch in Google Scholar
  • 14 Jacobs L D, Beck R W, Simon J H. et al . Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group.  N Engl J Med. 2000;  343 898-904
    CrossrefPubMedSearch in Google Scholar
  • 15 Comi G, Filippi M, Barkhof F. et al . Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study.  Lancet. 2001;  357 1576-1582
    CrossrefPubMedSearch in Google Scholar
  • 16 Stuve O, Bennett J L, Hemmer B. et al . Pharmacological Treatment of Early Multiple Sclerosis.  Drugs. 2008;  68 73-83
    PubMedSearch in Google Scholar
  • 17 Boskovic R, Wide R, Wolpin J. et al . The reproductive effects of beta interferon therapy in pregnancy: a longitudinal cohort.  Neurology. 2005;  65 807-811
    CrossrefPubMedSearch in Google Scholar
  • 18 Hoffmann L A, Kumpfel T, Heer I, Hohlfeld R. [Pregnancy and immunomodulatory therapy in multiple sclerosis patients].  Nervenarzt. 2006;  77 663-668, 670
    CrossrefPubMedSearch in Google Scholar
  • 19 Hartung H P, Polman C, Bertolotto A. et al . Neutralising antibodies to interferon beta in multiple sclerosis: expert panel report.  J Neurol. 2007;  254 827-837
    PubMedSearch in Google Scholar
  • 20 Hemmer B, Stuve O, Kieseier B. et al . Immune response to immunotherapy: the role of neutralising antibodies to interferon beta in the treatment of multiple sclerosis.  Lancet Neurol. 2005;  4 403-412
    PubMedSearch in Google Scholar
  • 21 Ziemssen T, Schrempf W. Glatiramer acetate: mechanisms of action in multiple sclerosis.  Int Rev Neurobiol. 2007;  79 537-570
    PubMedSearch in Google Scholar
  • 22 Johnson K P, Brooks B R, Cohen J A. et al . Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group [see comments].  Neurology. 1995;  45 1268-1276
    CrossrefPubMedSearch in Google Scholar
  • 23 Comi G, Filippi M, Wolinsky J S. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging - measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group.  Ann Neurol. 2001;  49 290-297
    CrossrefPubMedSearch in Google Scholar
  • 24 Filippi M, Rovaris M, Rocca M A. et al . Glatiramer acetate reduces the proportion of new MS lesions evolving into „black holes”.  Neurology. 2001;  57 731-733
    PubMedSearch in Google Scholar
  • 25 Filippi M, Wolinsky J S, Comi G. Effects of oral glatiramer acetate on clinical and MRI-monitored disease activity in patients with relapsing multiple sclerosis: a multicentre, double-blind, randomised, placebo-controlled study.  Lancet Neurol. 2006;  5 213-220
    PubMedSearch in Google Scholar
  • 26 Wolinsky J S, Narayana P A, O'Connor P. et al . Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial.  Ann Neurol. 2007;  61 14-24
    CrossrefPubMedSearch in Google Scholar
  • 27 Polman C H, O'Connor P W, Havrdova E. et al . A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.  N Engl J Med. 2006;  354 899-910
    CrossrefPubMedSearch in Google Scholar
  • 28 Krumbholz M, Pellkofer H, Gold R. et al . Delayed allergic reaction to natalizumab associated with early formation of neutralizing antibodies.  Arch Neurol. 2007;  64 1331-1333
    CrossrefPubMedSearch in Google Scholar
  • 29 Hellwig K, Schimrigk S, Fischer M. et al . Allergic and non-allergic delayed infusion reactions during natalizumab therapy.  Arch Neurol. 2008, im Druck; 
    PubMedSearch in Google Scholar
  • 30 Calabresi P A, Giovannoni G, Confavreux C. et al . The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL.  Neurology. 2007;  69 1391-1403
    CrossrefPubMedSearch in Google Scholar
  • 31 Chan A, Weilbach F X, Toyka K V, Gold R. Mitoxantrone induces cell death in peripheral blood leucocytes of multiple sclerosis patients.  Clin Exp Immunol. 2005;  139 152-158
    CrossrefPubMedSearch in Google Scholar
  • 32 Kopadze T, Dehmel T, Hartung H P. et al . Inhibition by mitoxantrone of in vitro migration of immunocompetent cells: a possible mechanism for therapeutic efficacy in the treatment of multiple sclerosis.  Arch Neurol. 2006;  63 1572-1578
    CrossrefPubMedSearch in Google Scholar
  • 33 Duddy M, Niino M, Adatia F. et al . Distinct Effector Cytokine Profiles of Memory and Naive Human B Cell Subsets and Implication in Multiple Sclerosis.  J Immunol. 2006;  178 6092-6099
    PubMedSearch in Google Scholar
  • 34 Hartung H P, Gonsette R, Konig N. et al . Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double blind, randomised multicentre trial.  Lancet. 2002;  360 2018-2025
    CrossrefPubMedSearch in Google Scholar
  • 35 Edan G, Miller D, Clanet M. et al . Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria [see comments].  J Neurol Neurosurg Psychiatry. 1997;  62 112-118
    CrossrefPubMedSearch in Google Scholar
  • 36 Debouverie M, Vandenberghe N, Morrissey S P. et al . Predictive parameters of mitoxantrone effectiveness in the treatment of multiple sclerosis.  Mult Scler. 2004;  10 407-412
    CrossrefPubMedSearch in Google Scholar
  • 37 Le Page E, Leray E, Taurin G. et al . Mitoxantrone as induction treatment in aggressive relapsing remitting Multiple Sclerosis: treatment response factors in a 5-year follow-up observational study of 100 consecutive patients.  J Neurol Neurosurg Psychiatry. 2008;  79 52-56
    CrossrefPubMedSearch in Google Scholar
  • 38 Morrissey S P, Le Page E, Edan G. Mitoxantrone in the treatment of multiple sclerosis.  Int MS J. 2005;  12 74-87
    PubMedSearch in Google Scholar
  • 39 Goffette S, van P V, Vanoverschelde J L. et al . Severe delayed heart failure in three multiple sclerosis patients previously treated with mitoxantrone.  J Neurol. 2005;  252 1217-1222
    CrossrefPubMedSearch in Google Scholar
  • 40 Ramtahal J, Jacob A, Das K, Boggild M. Sequential maintenance treatment with glatiramer acetate after mitoxantrone is safe and can limit exposure to immunosuppression in very active, relapsing remitting multiple sclerosis.  J Neurol. 2006;  253 1160-1164
    CrossrefPubMedSearch in Google Scholar
  • 41 Correale J, Rush C, Amengual A, Goicochea M T. Mitoxantrone as rescue therapy in worsening relapsing-remitting MS patients receiving IFN-beta.  J Neuroimmunol. 2005;  162 173-183
    CrossrefPubMedSearch in Google Scholar
  • 42 Edan G, Comi G, Lebrun D. et al . The French-Italian Mitoxantrone-Interferon-beta trial: a 3-year randomized study.  Multiple Sclerosis. 2007;  13, Suppl 2 S22-S23
    PubMedSearch in Google Scholar
  • 43 Soelberg S P. Intravenous polyclonal human immunoglobulins in multiple sclerosis.  Neurodegener Dis. 2008;  5 8-15
    CrossrefPubMedSearch in Google Scholar
  • 44 Haas J, Hommes O R. A dose comparison study of IVIG in postpartum relapsing-remitting multiple sclerosis.  Mult Scler. 2007;  13 900-908
    CrossrefPubMedSearch in Google Scholar
  • 45 Hommes O R, Sorensen P S, Fazekas F. et al . Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial.  Lancet. 2004;  364 1149-1156
    CrossrefPubMedSearch in Google Scholar
  • 46 Palace J, Rothwell P. New treatments and azathioprine in multiple sclerosis [letter].  Lancet. 1997;  350 261
    CrossrefPubMedSearch in Google Scholar
  • 47 Weiner H L, Mackin G A, Orav E J. et al . Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: Final report of the Northeast Cooperative Multiple Sclerosis Treatment group.  Neurology. 1993;  43 910-918
    PubMedSearch in Google Scholar
  • 48 Gold R, Jawad A, Miller D H. et al . Expert opinion: guidelines for the use of natalizumab in multiple sclerosis patients previously treated with immunomodulating therapies.  J Neuroimmunol. 2007;  187 156-158
    CrossrefPubMedSearch in Google Scholar

PD Dr. med. A. Chan

Neurologische Klinik
Ruhr-Universität Bochum
St. Josef-Hospital

Gudrunstr. 56

44791 Bochum

Email: andrew.chan@rub.de